Search

Your search keyword '"Xing, P. X."' showing total 129 results
Start Over Author "Xing, P. X."
129 results on '"Xing, P. X."'

1. Measurements of Normalized Differential Cross Sections of Inclusive $\eta$ Production in $e^{+}e^{-}$ Annihilation at Energy from 2.0000 to 3.6710 GeV

Author

BESIII Collaboration, Ablikim, M., Achasov, M. N., Adlarson, P., Afedulidis, O., Ai, X. C., Aliberti, R., Amoroso, A., An, Q., Anderle, D., Bai, Y., Bakina, O., Balossino, I., Ban, Y., Bao, H. -R., Batozskaya, V., Begzsuren, K., Berger, N., Berlowski, M., Bertani, M., Bettoni, D., Bianchi, F., Bianco, E., Bortone, A., Boyko, I., Briere, R. A., Brueggemann, A., Cai, H., Cai, X., Calcaterra, A., Cao, G. F., Cao, N., Cetin, S. A., Chang, J. F., Che, G. R., Chelkov, G., Chen, C., Chen, C. H., Chen, Chao, Chen, G., Chen, H. S., Chen, H. Y., Chen, M. L., Chen, S. J., Chen, S. L., Chen, S. M., Chen, T., Chen, X. R., Chen, X. T., Chen, Y. B., Chen, Y. Q., Chen, Z. J., Chen, Z. Y., Choi, S. K., Cibinetto, G., Cossio, F., Cui, J. J., Dai, H. L., Dai, J. P., Dbeyssi, A., de Boer, R. E., Dedovich, D., Deng, C. Q., Deng, Z. Y., Denig, A., Denysenko, I., Destefanis, M., De Mori, F., Ding, B., Ding, X. X., Ding, Y., Dong, J., Dong, L. Y., Dong, M. Y., Dong, X., Du, M. C., Du, S. X., Duan, Y. Y., Duan, Z. H., Egorov, P., Fan, Y. H., Fang, J., Fang, S. S., Fang, W. X., Fang, Y., Fang, Y. Q., Farinelli, R., Fava, L., Feldbauer, F., Felici, G., Feng, C. Q., Feng, J. H., Feng, Y. T., Fritsch, M., Fu, C. D., Fu, J. L., Fu, Y. W., Gao, H., Gao, X. B., Gao, Y. N., Gao, Yang, Garbolino, S., Garzia, I., Ge, L., Ge, P. T., Ge, Z. W., Geng, C., Gersabeck, E. M., Gilman, A., Goetzen, K., Gong, L., Gong, W. X., Gradl, W., Gramigna, S., Greco, M., Gu, M. H., Gu, Y. T., Guan, C. Y., Guan, Z. L., Guo, A. Q., Guo, L. B., Guo, M. J., Guo, R. P., Guo, Y. P., Guskov, A., Gutierrez, J., Han, K. L., Han, T. T., Hanisch, F., Hao, X. Q., Harris, F. A., He, K. K., He, K. L., Heinsius, F. H., Heinz, C. H., Heng, Y. K., Herold, C., Holtmann, T., Hong, P. C., Hou, G. Y., Hou, X. T., Hou, Y. R., Hou, Z. L., Hu, B. Y., Hu, H. M., Hu, J. F., Hu, S. L., Hu, T., Hu, Y., Huang, G. S., Huang, K. X., Huang, L. Q., Huang, X. T., Huang, Y. P., Hussain, T., Hölzken, F., Hüsken, N, der Wiesche, N. in, Jackson, J., Janchiv, S., Jeong, J. H., Ji, Q., Ji, Q. P., Ji, W., Ji, X. B., Ji, X. L., Ji, Y. Y., Jia, X. Q., Jia, Z. K., Jiang, D., Jiang, H. B., Jiang, P. C., Jiang, S. S., Jiang, T. J., Jiang, X. S., Jiang, Y., Jiao, J. B., Jiao, J. K., Jiao, Z., Jin, S., Jin, Y., Jing, M. Q., Jing, X. M., Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang, X. L., Kang, X. S., Kavatsyuk, M., Ke, B. C., Khachatryan, V., Khoukaz, A., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui, X., Kumar, N., Kupsc, A., Kühn, W., Lane, J. J., Larin, P., Lavezzi, L., Lei, T. T., Lei, Z. H., Lellmann, M., Lenz, T., Li, C., Li, C. H., Li, Cheng, Li, D. M., Li, F., Li, G., Li, H. B., Li, H. J., Li, H. N., Li, Hui, Li, J. R., Li, J. S., Li, Ke, Li, L. J, Li, L. K., Li, Lei, Li, M. H., Li, M. Y., Li, P. R., Li, Q. M., Li, Q. X., Li, R., Li, S. X., Li, T., Li, W. D., Li, W. G., Li, X., Li, X. H., Li, X. L., Li, X. Z., Li, Xiaoyu, Li, Y. G., Li, Z. J., Li, Z. X., Li, Z. Y., Liang, C., Liang, H., Liang, Y. F., Liang, Y. T., Liao, G. R., Liao, L. Z., Libby, J., Limphirat, A., Lin, C. C., Lin, D. X., Lin, T., Liu, B. J., Liu, B. X., Liu, C., Liu, C. X., Liu, F. H., Liu, Fang, Liu, Feng, Liu, G. M., Liu, H., Liu, H. B., Liu, H. M., Liu, Huanhuan, Liu, Huihui, Liu, J. B., Liu, J. Y., Liu, K., Liu, K. Y., Liu, Ke, Liu, L., Liu, L. C., Liu, Lu, Liu, M. H., Liu, P. L., Liu, Q., Liu, S. B., Liu, T., Liu, W. K., Liu, W. M., Liu, X., Liu, Y., Liu, Y. B., Liu, Z. A., Liu, Z. D., Liu, Z. Q., Lou, X. C., Lu, F. X., Lu, H. J., Lu, J. G., Lu, X. L., Lu, Y., Lu, Y. P., Lu, Z. H., Luo, C. L., Luo, M. X., Luo, T., Luo, X. L., Lyu, X. R., Lyu, Y. F., Ma, F. C., Ma, H., Ma, H. L., Ma, J. L., Ma, L. L., Ma, M. M., Ma, Q. M., Ma, R. Q., Ma, T., Ma, X. T., Ma, X. Y., Ma, Y., Ma, Y. M., Maas, F. E., Maggiora, M., Malde, S., Mao, Y. J., Mao, Z. P., Marcello, S., Meng, Z. X., Messchendorp, J. G., Mezzadri, G., Miao, H., Min, T. J., Mitchell, R. E., Mo, X. H., Moses, B., Muchnoi, N. Yu., Muskalla, J., Nefedov, Y., Nerling, F., Nie, L. S., Nikolaev, I. B., Ning, Z., Nisar, S., Niu, Q. L., Niu, W. D., Niu, Y., Olsen, S. L., Ouyang, Q., Pacetti, S., Pan, X., Pan, Y., Pathak, A., Patteri, P., Pei, Y. P., Pelizaeus, M., Peng, H. P., Peng, Y. Y., Peters, K., Ping, J. L., Ping, R. G., Plura, S., Prasad, V., Qi, F. Z., Qi, H., Qi, H. R., Qi, M., Qi, T. Y., Qian, S., Qian, W. B., Qiao, C. F., Qiao, X. K., Qin, J. J., Qin, L. Q., Qin, L. Y., Qin, X. S., Qin, Z. H., Qiu, J. F., Qu, Z. H., Redmer, C. F., Ren, K. J., Rivetti, A., Rolo, M., Rong, G., Rosner, Ch., Ruan, S. N., Salone, N., Sarantsev, A., Schelhaas, Y., Schoenning, K., Scodeggio, M., Shan, K. Y., Shan, W., Shan, X. Y., Shang, Z. J, Shangguan, J. F., Shao, L. G., Shao, M., Shen, C. P., Shen, H. F., Shen, W. H., Shen, X. Y., Shi, B. A., Shi, H., Shi, H. C., Shi, J. L., Shi, J. Y., Shi, Q. Q., Shi, S. Y., Shi, X., Song, J. J., Song, T. Z., Song, W. M., Song, Y. J., Song, Y. X., Sosio, S., Spataro, S., Stieler, F., Su, Y. J., Sun, G. B., Sun, G. X., Sun, H., Sun, H. K., Sun, J. F., Sun, K., Sun, L., Sun, S. S., Sun, T., Sun, W. Y., Sun, Y., Sun, Y. J., Sun, Y. Z., Sun, Z. Q., Sun, Z. T., Tang, C. J., Tang, G. Y., Tang, J., Tang, M., Tang, Y. A., Tao, L. Y., Tao, Q. T., Tat, M., Teng, J. X., Thoren, V., Tian, W. H., Tian, Y., Tian, Z. F., Uman, I., Wan, Y., Wang, S. J., Wang, B., Wang, B. L., Wang, Bo, Wang, D. Y., Wang, F., Wang, H. J., Wang, J. J., Wang, J. P., Wang, K., Wang, L. L., Wang, M., Wang, Meng, Wang, N. Y., Wang, S., Wang, T., Wang, T. J., Wang, W., Wang, W. P., Wang, X., Wang, X. F., Wang, X. J., Wang, X. L., Wang, X. N., Wang, Y., Wang, Y. D., Wang, Y. F., Wang, Y. L., Wang, Y. N., Wang, Y. Q., Wang, Yaqian, Wang, Yi, Wang, Z., Wang, Z. L., Wang, Z. Y., Wang, Ziyi, Wei, D. H., Weidner, F., Wen, S. P., Wen, Y. R., Wiedner, U., Wilkinson, G., Wolke, M., Wollenberg, L., Wu, C., Wu, J. F., Wu, L. H., Wu, L. J., Wu, X., Wu, X. H., Wu, Y., Wu, Y. H., Wu, Y. J., Wu, Z., Xia, L., Xian, X. M., Xiang, B. H., Xiang, T., Xiao, D., Xiao, G. Y., Xiao, S. Y., Xiao, Y. L., Xiao, Z. J., Xie, C., Xie, X. H., Xie, Y., Xie, Y. G., Xie, Y. H., Xie, Z. P., Xing, H. X., Xing, T. Y., Xu, C. F., Xu, C. J., Xu, G. F., Xu, H. Y., Xu, M., Xu, Q. J., Xu, Q. N., Xu, W., Xu, W. L., Xu, X. P., Xu, Y. C., Xu, Z. P., Xu, Z. S., Yan, F., Yan, L., Yan, W. B., Yan, W. C., Yan, X. Q., Yang, H. J., Yang, H. L., Yang, H. X., Yang, Tao, Yang, Y., Yang, Y. F., Yang, Y. X., Yang, Yifan, Yang, Z. W., Yao, Z. P., Ye, M., Ye, M. H., Yin, J. H., You, Z. Y., Yu, B. X., Yu, C. X., Yu, G., Yu, J. S., Yu, T., Yu, X. D., Yu, Y. C., Yuan, C. Z., Yuan, J., Yuan, L., Yuan, S. C., Yuan, Y., Yuan, Y. J., Yuan, Z. Y., Yue, C. X., Zafar, A. A., Zeng, F. R., Zeng, S. H., Zeng, X., Zeng, Y., Zeng, Y. J., Zhai, X. Y., Zhai, Y. C., Zhan, Y. H., Zhang, A. Q., Zhang, B. L., Zhang, B. X., Zhang, D. H., Zhang, G. Y., Zhang, H., Zhang, H. C., Zhang, H. H., Zhang, H. Q., Zhang, H. R., Zhang, H. Y., Zhang, J., Zhang, J. J., Zhang, J. L., Zhang, J. Q., Zhang, J. S., Zhang, J. W., Zhang, J. X., Zhang, J. Y., Zhang, J. Z., Zhang, Jianyu, Zhang, L. M., Zhang, Lei, Zhang, P., Zhang, Q. Y., Zhang, R. Y, Zhang, Shuihan, Zhang, Shulei, Zhang, X. D., Zhang, X. M., Zhang, X. Y., Zhang, Y., Zhang, Y. T., Zhang, Y. H., Zhang, Y. M., Zhang, Yan, Zhang, Yao, Zhang, Z. D., Zhang, Z. H., Zhang, Z. L., Zhang, Z. Y., Zhang, Z. Z., Zhao, G., Zhao, J. Y., Zhao, J. Z., Zhao, Lei, Zhao, Ling, Zhao, M. G., Zhao, N., Zhao, R. P., Zhao, S. J., Zhao, Y. B., Zhao, Y. X., Zhao, Z. G., Zhemchugov, A., Zheng, B., Zheng, B. M., Zheng, J. P., Zheng, W. J., Zheng, Y. H., Zhong, B., Zhong, X., Zhou, H., Zhou, J. Y., Zhou, L. P., Zhou, S., Zhou, X., Zhou, X. K., Zhou, X. R., Zhou, X. Y., Zhou, Y. Z., Zhu, J., Zhu, K., Zhu, K. J., Zhu, K. S., Zhu, L., Zhu, L. X., Zhu, S. H., Zhu, S. Q., Zhu, T. J., Zhu, W. D., Zhu, Y. C., Zhu, Z. A., Zou, J. H., and Zu, J.

Subjects
High Energy Physics - Experiment
Abstract

Using data samples collected with the BESIII detector operating at the BEPCII storage ring, the cross section of the inclusive process $e^{+}e^{-} \to \eta + X$, normalized by the total cross section of $e^{+}e^{-} \to \text{hadrons}$, is measured at eight center-of-mass energy points from 2.0000 GeV to 3.6710 GeV. These are the first measurements with momentum dependence in this energy region. Our measurement shows a significant discrepancy from calculations with the existing fragmentation functions. To address this discrepancy, a new QCD analysis is performed at the next-to-next-to-leading order with hadron mass corrections and higher twist effects, which can explain both the established high-energy data and our measurements reasonably well., Comment: 9 pages, 2 figures

Published
2024
Full Text
View/download PDF

3. Intermixing Induced Anisotropy Variations in CoB-based Chiral Multilayer Films

Author

Tan, H. K., Lim, Royston J. J., Seng, H. L., Shanmugam, J., Ko, H. Y. Y., Cheng, X. M., Putra, V., Xing, Z. X., Soumyanarayanan, Anjan, and Ho, Pin

Subjects
Condensed Matter - Materials Science, Condensed Matter - Mesoscale and Nanoscale Physics
Abstract

We examine the atomic intermixing phenomenon in three distinct amorphous CoB-based multilayer thin film platforms - Pt/CoB/Ir, Ir/CoB/Pt and Pt/CoB/MgO - which are shown to stabilise room-temperature chiral magnetic textures. Intermixing occurs predominantly between adjacent metallic layers. Notably, it is stack-order dependent, and particularly extensive when Ir sits atop CoB. Intermixing induced variations in magnetic properties are ascribed to the formation of magnetic dead layer arising from CoIr alloying in the metallic stacks. It also produces systematic variations in saturation magnetization, by as much as 30%, across stacks. Crucially, the resulting crossover CoB thickness for the transition from perpendicular to in-plane magnetic anisotropy differs by more than 2x across the stacks. Finally, with thermal annealing treatment over moderate temperatures of 150-300 degree Celsius, the magnetic anisotropy increases monotonically across all stacks, coupled with discernibly larger Hc for the metallic stacks. These are attributed to thermally induced CoPt alloying and MgO crystallization in the metallic and oxide stacks, respectively. Remarkably, the CoB in the Pt/CoB/MgO stacks retains its amorphous nature after annealing. Our results set the stage for harnessing the collective attributes of amorphous CoB-based material platforms and associated annealing processes for modulating magnetic interactions, enabling the tuning of chiral magnetic texture properties in ambient conditions., Comment: Supplementary information included

Published
2021
Full Text
View/download PDF

19. Effects of SIRT1/Akt pathway on chronic inflammatory response and lung function in patients with asthma.

Author

ZHANG, Y.-Z., WU, Q.-J., YANG, X., XING, X.-X., CHEN, Y.-Y., and WANG, H.

Abstract

OBJECTIVE: Asthma is the most common chronic airway inflammatory disease. Sirtuin 1 (SIRT1) exerts a crucial effect on regulating chronic inflammatory responses. Therefore, this study aims to explore the effect of SIRT1 on the pathogenesis of asthma. MATERIALS AND METHODS: Serum level of SIRT1 in asthma patients and healthy controls was detected by Western blot. Correlation between SIRT1 level and pulmonary function in asthma patients was analyzed. Subsequently, asthma model in mouse was established. Primary airway epithelial cells were extracted from asthma mice and control mice to detect SIRT1 level. Furthermore, relative levels of Akt and interleukin 6 (IL-6) were detected in 16HBE cells. Regulatory effects of Akt on SIRT1 in 16HBE cells were determined as well. RESULTS: SIRT1 was highly expressed in serum of asthma patients, which was negatively correlated with FEV1/FVC (r=-0.27, **p<0.01). Both mRNA and protein levels of SIRT1 were downregulated in primary airway epithelial cells extracted from asthma mice compared with those from controls. SIRT1 knockdown in 16HBE cells upregulated IL-6 expression, which was reversed by Akt inhibitors. CONCLUSIONS: SIRT1 regulates IL-6 level via Akt pathway, thereafter affecting pulmonary function in asthma patients. [ABSTRACT FROM AUTHOR]

Published
2019

20. Down-regulation of Treg by interference of enhances the killing effect of CIK on leukemia cell HL-60.

Author

XING, X.-X., ZHAO, X.-Y., and DONG, Y.-C.

Abstract

OBJECTIVE: Cytokine-induced killer cells (CIK) is a type of immune cell with antitumor activity induced by a variety of cytokines. Regulatory T cells (Treg) is a T cell subgroup featured as immunosuppressive function. Existing CIK cultivation system may inevitably induce Treg. Forkhead box protein 3 (Foxp3) is an essential transcription factor for Treg function. This study aimed to investigate the effects of CIK on the leukemia cell HL-60. MATERIALS AND METHODS: This work silenced Foxp3 expression on the basis of CIK induction, aiming to investigate its killing effect on HL-60 cells. Peripheral blood mononuclear cells were separated and differentiated to CIK in vitro. CD3+CD56+ and CD4+CD25+Foxp3+ Treg cells were detected by flow cytometry. CIK cells were co-cultured with HL-60 cells under the effectortarget ratio at 20:1, 10:1, and 5:1, respectively. The killing activity of CIK on HL-60 cells was determined by CCK-8 assay. RESULTS: The ratio of CD3+, CD3+CD8+, and CD3+CD56+ cells gradually increased during CIK induction. Foxp3 interference significantly reduced Treg cell ratio on the 7th day (p < 0.05). Treg cell ratio was significantly lower in Foxp3 interference group at 1.62% ± 0.07% compared with control (p < 0.05). The killing activity of CIK on HL-60 cells enhanced following the increase of effectortarget ratio. Interference of Foxp3 significantly elevated the killing activity of CIK on HL-60 cells with effector-target ratio dependence (p < 0.05). CIK can effectively suppress HL-60 cell growth. Treg significantly inhibited the anti-tumor effect of CIK. CONCLUSIONS: Interference of Foxp3 expression significantly declined Treg level and attenuated its suppression impact on CIK, thus enhancing the killing effect of CIK on HL-60 cells.. [ABSTRACT FROM AUTHOR]

Published
2018

21. Construction and characterization of a chimeric receptor containing the cytoplasmic domain of MUC1 mucin

Author

MEERZAMAN, DAOUD, XING, P. X., and KIM, K. CHUL

Subjects
Mucins -- Research, Cell receptors -- Research, Cellular signal transduction -- Research, Biological sciences
Abstract

Meerzaman, Daoud, P. X. Xing, and K. Chul Kim. Construction and characterization of a chimeric receptor containing the cytoplasmic domain of MUC1 mucin. Am. J. Physiol. Lung Cell. Mol. Physiol. 278: L625-L629, 2000.--MUC1 mucin is a transmembrane glycoprotein that is highly expressed in various cancer cell lines and is also present in most of the glandular epithelial cells including the airway. Although the presence of numerous phosphorylation sites in its cytoplasmic domain suggests its potential role as a receptor, the unavailability of a ligand for MUC1 mucin has limited our understanding of its function. In this paper, we tried to circumvent this problem by constructing a chimeric receptor containing the cytoplasmic domain of MUC1 mucin, which can be phosphorylated on activation. To this end, we constructed a chimeric plasmid vector (pCD8/MUC1) by replacing the extracellular and transmembrane domains of human MUC1 mucin with those of human CD8. Transient transfection of the vector into COS-7 cells resulted in expression of the chimeric receptor on the surface of the COS-7 cells as judged by immunologic assays with various antibodies as well as by fluorescence-activated cell-sorting analysis. Treatment of the transfected COS-7 cells with an anti-CD8 antibody resulted in a significant increase in phosphorylation of tyrosine moieties of the chimeric receptor. This chimeric receptor will serve as a powerful tool in elucidating the signaling mechanism as well as the functional role of MUC1 mucin in the airway. CD8; phosphorylation; signal transduction

Published
2000

23. Influence of roll with cone defect on shape in a six-high mill and its control model

Author

Bai, Z. H., Xing, B. X., Zhao, W. Q., Liu, Y. X., Qian, C., and Zhang, M. J.

Abstract

Cone defect in rolls may be caused by bad grinding. Cone defect leads to shape defect in unilateral waves of the finished strip. By using a six-high mill as example and by considering the features of the devices and technology, an influence model of roll with cone defect and a suitable shape control technology of a six-high mill was established to guarantee good shape. This model was then applied to a production practice of 1220 cold continuous rolling units. Quantitative analysis of different kinds of roll with cone defect and its effect on shape control shows that the additional shape caused by cone defect are unilateral waves. In conclusion, optimising the amount of tilt settings can effectively control the additional shape caused by cone defect, which provides enterprises with a useful reference for the high-precision control of shape.

Published
2017
Full Text
View/download PDF

25. Histone deacetylase inhibitor M344 significantly improves nuclear reprogramming, blastocyst quality, and in vitro developmental capacity of cloned pig embryos1

Author

Jin, L., Guo, Q., Zhu, H.-Y., Xing, X.-X., Zhang, G.-L., Xuan, M.-F., Luo, Q.-R., Luo, Z.-B., Wang, J.-X., Choe, H.-M., Paek, H.-J., Yin, X.-J., and Kang, J.-D.

Abstract

M344 is a novel histone deacetylase inhibitor. There is no report on the effect of M344 treatment on the development of pig embryos after somatic cell nuclear transfer (SCNT). In the present study, we investigated the effect of M344 on the blastocyst formation rate in cloned embryos, acetylation level of histone H4 lysine 12 (AcH4K12), and the expression of pluripotency-related genes Oct4, NANOG, and SOX2. Our results indicated that treatment with 5 µMM344 for 6 h improved the development of porcine embryos, in comparison with the untreated group (25.1% ± 5.0 vs. 10.9% ± 2.4; P< 0.05). Moreover, M344-treated embryos had increased average fluorescence intensity of AcH4K12 at the pseudo-pronuclear stage (P< 0.05). However, no differences exist in Oct4, NANOG, and SOX2 expression in M344-treated and untreated SCNT blastocysts. In evaluating the effect of M344 on in vivo development, 845 M344-treated embryos were transferred into 3 surrogates, 1 of whom became pregnant and developed 3 fetuses. These findings suggested that M344 elevated the level of histone acetylation, facilitated the nuclear programming, and subsequently improved the developmental competence of pig SCNT embryos.

Published
2017
Full Text
View/download PDF

26. Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions

Author

Xing, P X, Reynolds, K, Pietersz, G A, and McKenzie, I F

Subjects
Antigen-Antibody Reactions, Epitopes, Membrane Glycoproteins, Antigens, Neoplasm, Molecular Sequence Data, Mucin-1, Antibodies, Monoclonal, Humans, Breast Neoplasms, Female, Amino Acid Sequence, Peptide Fragments, Research Article
Abstract

Monoclonal anti-mucine antibodies BC1, BC2 and BC3 produced using human milk fat globule membrane react with a synthetic peptide p1-24 (PDTRPAPGSTAPPAHGVTSAPDTR) representing the repeating amino acid sequence of the mucin core protein. The minimum epitope recognized by these three monoclonal antibodies (mAb) in p1-24 was contained in the five amino acids APDTR. To analyse the variation of position of the epitope, various modifications of the APDTR sequence were made by synthesizing peptides and testing by direct binding and inhibition enzyme-linked immunosorbent assays. Firstly, peptides p13-32 and C-p13-32, in which the epitope APDTR was placed in the middle instead of the C-terminal as in p1-24, were examined. These peptides had a greater reaction with mAb BC1, BC2 and BC3 compared with the reaction with p1-24. Secondly, A-p1-24 and TSA-p1-24 were made wherein two APDTR epitopes were present--these peptides were shown to bind two IgG antibody molecules. Finally, the contribution of each amino acid in the APDTR epitope was studied using the pepscan polyethylene rods, making all 20 of the amino acid substitutions in each position for SAPDTR (the minimum epitope APDTR with an adjacent amino acid S). In the 120 peptides examined there were some 'permissible' substitutions in A, D and T but not in P or R for BC1 and BC2; there were more 'permissible' substitutions for BC3; different substitution patterns were found with each antibody and some substitutions gave an increased reaction compared with the native peptide SAPDTR. The studies are of value in analysing the reaction of antibodies with epitopes expressed in breast cancer and in determining the antigenicity of synthetic peptides.

Published
1991

27. Seasonal variation pattern of NH4+-N/NO3--N ratio and δ15NH4+ value in rainwater in Yangtze River Delta.

Author

Xie, Y. X., Zhang, S. L., Zhao, X., Xiong, Z. Q., and Xing, G. X.

Abstract

By using a customized manual rainwater sampler made of polyvinyl chloride plastic, the molar ratio of NH4+ -N/NO3(-) -N and the natural 15N abundance of NH4+ (delta 15 NH4+ in rainwater was monitored all year round from June 2003 to July 2005 at three observation sites (Changshu, Nanjing, and Hangzhou) in the Yangtze River Delta. The results indicated that at the three sites, the NH4+ -N/NO3(-) -N ratio and the delta 15 NH4+ value in rainwater had the similar seasonal variation trend, being more obvious in Changshu (rural monitoring type) site than in Nanjing (urban monitoring type) and Hangzhou (urban-rural monitoring type) sites. The NH4+ -N/NO3(-) -N ratio peaked from early June to early August, declined gradually afterwards, and reached the bottom in winter; while the delta 15 NH4+ value was negative from late June to mid-August, turned positive from late August to mid or late November, became negative again when winter dominated from December to March, but turned positive again in next May and negative again in next July. These seasonal variation patterns of NH4+ -N/NO3(-) -N ratio and delta 15 NH4+ value were found in relation to the application of chemical nitrogen fertilizers during different crop growth periods, and also, the alternation of seasons and the NH3 volatilization from other NH3 emission sources (including excrements of human and animals, nitrogen- polluted water bodies, and organic nitrogen sources, etc.), which could be taken as an indicator of defining the sources and form composition of NH4+ in atmospheric wet deposition and the intensity of various terrestrial NH3 emission sources. [ABSTRACT FROM AUTHOR]

Published
2008

28. Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.

Author

Hu, X. F., Li, J., Yang, E., Vandervalk, S., and Xing, P. X.

Subjects
DOXORUBICIN, LEUKEMIA, TUMOR growth, MULTIDRUG resistance, EPIDERMAL growth factor, PROTEIN kinases
Abstract

Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Here, we report for the first time that oncoprotein Cripto, a founding member of epidermal growth factor-Cripto-FRL, 1-Criptic family is overexpressed in the CEM/A7R cells, and anti-Cripto monoclonal antibodies (Mab) inhibited CEM/A7R cell growth both in vitro and in an established xenograft tumour in severe combined immunodeficiency mice. Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC). In particular, the combination of anti-Cripto Mab at less than 50% of inhibition concentrations with noncytotoxic concentrations of EPI or DAU inhibited more than 90% of CEM/A7R cell growth. Cripto Mab slightly inhibited Pgp expression, and had little effect on Pgp function, indicating that a mechanism independent of Pgp was involved in overcoming MDR. We demonstrated that anti-Cripto Mab-induced CEM/A7R cell apoptosis, which was associated with an enhanced activity of the c-Jun N-terminal kinase/stress-activated protein kinase and inhibition of Akt phosphorylation, resulting in an activation of mitochondrial apoptosis pathway as evidenced by dephosphorylation of Bad at Ser136, Bcl-2 at Ser70 and a cleaved caspase-9.British Journal of Cancer (2007) 96, 918–927. doi:10.1038/sj.bjc.6603641 www.bjcancer.com Published online 6 March 2007 [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

30. Semisolid stirring brazing of SiCp/A356 composites with Zn27Al filler metal in air

Author

Xu, H B, Xing, Q X, Zeng, Y L, Luo, Y, and Du, C H

Abstract

The semisolid brazing process of SiCp/A356 composites was investigated. The effects of temperature on the microstructure of the filler metal and the joints are discussed in this paper. The research results show that with increasing temperature, the solid fraction of the filler metal decreases. Moreover, the SiCp/A356 composites can be effectively joined with the semisolid filler metal by optimising the stirring temperature. It can be found that most of the oxide film on the surface of the composites is disrupted by mechanical stirring. In this case, the metallurgical bonds formed at the interface between the filler metal and the base materials. Since the semisolid temperature range of the filler metal is narrow, the accurate controlling of the weld pool temperature must be considered.

Published
2011
Full Text
View/download PDF

31. Discrimination between alternatively spliced STP-A and -B isoforms of CD46.

Author

Xing, P.-X., Russell, S., Prenzoska, J., and Mckenzie, I.F.C.

Subjects
*CD antigens, *GLYCOPROTEINS, *CELL surface antigens, *MEMBRANE proteins, *PROTEINS, *BIOLOGICAL membranes
Abstract

CD46 (membrane cofactor protein; MCP) is ubiquitously expressed on nucleated human cells; it has a protective function, binding C3b and C4b, which are then cleaved by serum factor I. CD46 molecules (55 000-65 000 MW) have four short consensus repeats (SCR): the function of SCR-1 and -2 is unknown; SCR-3 and 4 bind C3b and C4b. These are succeeded by the STP region, which can contain three separate regions (STP-A, -B, -C) rich in serine, threonine and proline and which are heavily glycosylated, succeeded by transmembrane and cytoplasmic tail regions (of which there are several). Multiple isoforms exist due to the different splicing of exons: STP-A and -B can thus be present or absent. So far these products can only be detected separately by polymerase chain reaction (PCR) and RNA studies; we now describe their detection by anti-peptide antibodies. Peptides whose sequences corresponded with those of STP-A and STP-B were synthesized and used for the immunization of mice; although they differ in only seven of 21 amino acids, monocional antibodies (mAb) that reacted specifically with STP-A but not with STP-B, and mAb that reacted specifically with STP-B but not with STP-A, were produced; these reacted specifically with native CD46 on human tissues and cell lines. STP-A mAb reacted with tissues in which STP-A RNA had been found, some leukaemias and cell lines; in normal tissue expression was mainly found in the intestine (large and small) and salivary gland. Anti-STP-B reacted with most tissues and cell lines. The antibodies should be of use in defining the expression and function of CD46 in different tissues. [ABSTRACT FROM AUTHOR]

Published
1994

32. Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

Author

Xing, P.-X., Reynolds, K., Pietersz, G.A., and McKenzie, I.F.C.

Subjects
*IMMUNOGLOBULINS, *BREAST milk, *AMINO acid sequence, *PEPTIDES, *MILKFAT, *ENZYME-linked immunosorbent assay
Abstract

Monoclonal anti-mucine antibodies BC1, BC2 and BC3 produced using human milk fat globule membrane react with a synthetic peptide p1-24 (PDTRPAPGSTAPPAHGVTSAPDTR) representing the repeating amino acid sequence of the mucin core protein. The minimum epitope recognized by these three monoclonal antibodies (mAb) in p1-24 was contained in the five amino acids APDTR. To analyse the variation of position of the epitope, various modifications of the APDTR sequence were made by synthesizing peptides and testing by direct binding and inhibition enzyme-linked immunosorbent assays. Firstly, peptides p13-32 and C-p13-32, in which the epitope APDTR was placed in the middle instead of the C-terminal as in p1-24, were examined. These peptides had a greater reaction with mAb BC1, BC2 and BC3 compared with the reaction with p1-24. Secondly, A-p1-24 and TSA-p1-24 were made wherein two APDTR epitopes were present—these peptides were shown to bind two IgG antibody molecules. Finally, the contribution of each amino acid in the APDTR epitope was studied using the pepscan polyethylene rods, making all 20 of the amino acid substitutions in each position for SAPDTR (the minimum epitope APDTR with an adjacent amino acid S). In the 120 peptides examined there were some 'permissible' substitutions in A, D and T but not in P or R for BCi and BC2; there were more 'permissible' substitutions for BC3; different substitution patterns were found with each antibody and some substitutions gave an increased reaction compared with the native peptide SAPDTR. The studies are of value in analysing the reaction of antibodies with epitopes expressed in breast cancer and in determining the antigenicity of synthetic peptides. [ABSTRACT FROM AUTHOR]

Published
1991

35. Characteristics of a breast cancer-associated antigen defined by RCC-1 antibody.

Author

Tjandra, J. J., Zalcberg, J., Xing, P.-X., and McKenzie, I. F. C.

Subjects
BREAST cancer, MOLECULAR cloning, LYMPH nodes, CARRIER proteins, BREAST milk, DIGESTIVE enzymes
Abstract

This study reports the characterization of a breast cancer-associated antigen identified by murine monoclonal antibody (MoAb) RCC-I (formerly called 24-1 71). Immunoperoxidase staining indicated that RCC-1 recognized an antigen highly expressed in malignant tumours of breast origin, and no reactivity was noted with connective tissue, muscle or lymph nodes, which is an important consideration in its successful use in immunolymphoscintigraphy. The RCC-1 was shown to consist of 94 000 dalton disulfide-bonded dimers which were shown to be different from the transferrin receptor. In addition, the antibody RCC-1 did not react with components of human milk or with an antigenic peptide derived from the core protein of a mammary mucin. Chemical treatment and enzymatic digestion suggested that the epitope recognized by antibody RCC-1 was protein as it was resistant to neuraminidase and periodate treatment but was sensitive to trypsin. The RCC-1-defined antigen detects a novel breast cancer associated antigen. [ABSTRACT FROM AUTHOR]

Published
1990
Full Text
View/download PDF

36. Monoclonal antibodies reactive with mucin expressed in breast cancer.

Author

Xing, P.-X., Tjandra, J. J., Stacker, S. A., Teh, J. G., Thompson, C. H., McLaughlin, P. J., and McKenzie, I. F. C.

Subjects
IMMUNOGLOBULINS, GLOBULINS, BLOOD proteins, BREAST cancer, MONOCLONAL antibodies
Abstract

Three murine monoclonal antibodies (BC1, BC2 and BC3) were developed against human milk fat globule membrane (HMFGM). By immunoperoxidase staining, it was found that the antigenic determinants had a predominant distribution in breast cancer tissue. In addition, the antibodies reacted preferentially with mucin derived from human milk rather than that derived from the breast cancer cell line ZR75; they also recognized polymorphic high molecular weight components (MW≥230 000) in serum and in human milk fat globule membrane. Thus the antibodies appear to react with a component of the family of mucins found in breast cancer and human milk and it appears likely that at least part of each epitope is protein in nature. Antibodies BCI, BC2 and BC3 recognized related but not identical epitopes, and they appear to be co-expressed on the same molecules as 3E1-2-defined antigen (mammary serum antigen, MSA) which is also a member of the family of breast cancer-rotated mucin. However, the 3E1-2 epitope is distinct and non-cross-reactive with those described for BCI, BC2 and BC3. The BC2 and BC3 defined epitopes were examined for their value in serum assays. Immunoassay was developed with a combination of two antibodies, using antibody BC3 for antigen capture and antibody BC2 or 3E1-2 for antigen detection and gave reasonable sensitivity (∼85%) and specificity (∼95%) in such serum tests for breast cancer. In a limited study, these tests appeared to complement the MSA test in the detection of breast cancer. [ABSTRACT FROM AUTHOR]

Published
1989
Full Text
View/download PDF

38. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells

Author

Wykes, M., MacDonald, K. P. A., Tran, M., Quin, R. J., Xing, P. X., Gendler, S. J., Hart, D. N. J., and McGuckin, M. A.

Abstract

The MUC1 mucin (CD227) is a cell surface mucin originally thought to be restricted to epithelial tissues. We report that CD227 is expressed on human blood dendritic cells (DC) and monocyte‐derived DC following in vitro activation. Freshly isolated murine splenic DC had very low levels of CD227; however, all DC expressed CD227 following in vitro culture. In the mouse spleen, CD227 was seen on clusters within the red pulp and surrounding the marginal zone in the white pulp. Additionally, we confirm CD227 expression by activated human T cells and show for the first time that the CD227 cytoplasmic domain is tyrosine‐phosphorylated in activated T cells and DC and is associated with other phosphoproteins, indicating a role in signaling. The function of CD227 on DC and T cells requires further elucidation.

Published
2002
Full Text
View/download PDF

39. Kinetics of the reactive sintering of kaolinite-aluminum hydroxide extrudate

Author

Liu, Ya-Fei Y.-F., Liu, Xing-Qin X.-Q., Tao, Shan-Wen S.-W., Meng, Guang-Yao G.-Y., and Sorensen, O. Toff O.T.

Abstract

The kinetics of the reactive sintering process of the extrudate made of a kaolinite and aluminum hydroxide mixture is investigated by means of stepwise isothermal dilatometry (SID) accompanied with XRD, SEM and other techniques. We find that the process can be divided into three stages in total, and the isothermal shrinkage data can be well-fitted according to Makipirtti-Meng equation: d Y /d t = nk ( T ) Y (1− Y )[(1− Y )/ Y ], where Y is the fractional densification function. The apparent activation energy E a values are obtained as 2972±461 kJ mol for 950-1100 °C, 1056±74 kJ mol for 1200-1300 °C, and 792.7±17.0 kJ mol for 1300-1450 °C. The sintering shrinkage mechanisms in different temperature ranges are discussed, with reference to phase, pore and microstructure development. This study is helpful to control the microstructure and properties of the porous mullite-corundum ceramics.

Published
2002
Full Text
View/download PDF

45. Immunotherapy for breast cancer with synthetic peptides

Author

McKenzie, I.F.C., Apostolopoulos, V., and Xing, P.-X.

Subjects
Breast cancer, Immunotherapy -- Research, Business, Health care industry
Abstract

AUTHORS: I.F.C. McKenzie, V. Apostolopoulos and P.-X. Xing. The Austin Research Institute, The Austin Hospital, Heidelberg, Victoria, Australia. According to an abstract presented by the authors to a plenary session [...]

Published
1993

46. Peptide Binding Sites Recognized by Anti-Mucin (MUC2) Monoclonal Antibodies.

Author

Xing, P.-X., Apostolopoulos, V., Prenzoska, J., Devine, P. L., and McKenzie, I. F. C.

Subjects
MUCINS, PEPTIDES, MONOCLONAL antibodies, GASTROINTESTINAL system, IMMUNOGENETICS, POLYETHYLENE, AMINO acids
Abstract

Multiple genes coding for human mucins have been identified (MUC 1-5) and here monoclonal antibodies (MoAb) to a gastrointestinal mucin-MUC2 are examined. The antibodies were made to a synthetic peptide representing a single repeat in the core protein of the variable number of tandem repeat region. Using the six-mer overlapping peptides synthesized on polyethylene pins, different binding sites were detected by five anti-MUC 2 MoAbs. These contained amino acids: STTT, PTT, GTQTP, TPTP and PTTT (one antibody), and TPTPT. The repeat region of M UC2 essentially is hydrophobic, but contain useful immunogenic sites. This information will be useful for studying the structure and function of MUC2. [ABSTRACT FROM AUTHOR]

Published
1993
Full Text
View/download PDF

47. BS10 THE PROGNOSTIC SIGNIFICANCE OF THE OVEREXPRESSION OF THE GROWTH FACTOR CRIPTO IN PATIENTS WITH BREAST CANCER.

Author

Carmalt, H. L., Gong, Y. P., Yarrow, P. M., Lin, B. P. C., Xing, P. X., and Gillett, D. J.

Subjects
BREAST cancer, CANCER patients, PROGNOSTIC tests, EPIDERMAL growth factor, GROWTH factors, IMMUNOHISTOCHEMISTRY
Abstract

Purpose To determine the prognostic significance and long term survival of breast cancer patients with overexpression of the epidermal growth factor Cripto. Methodology 120 formalin fixed paraffin embedded breast cancer specimens were constructed on a tissue microarray and detection of Cripto carried out by immunohistochemical staining. Patients were treated between 1989 and 1995 and the median follow up was 125 months. We examined the association of Cripto positivity with age, menopausal status, grade and size of tumour, lymph node status, tumour type, ER/PR/HER2 status, Ki67 and Nottingham Prognostic Index (NPI). Results 48% of patients were Cripto positive. We demonstrated a significant association between overexpression of Cripto and NPI (p < 0.01), grade of tumour (p < 0.01), progesterone receptor (p = 0.02), Ki 67 (p = 0.02), tumour type (p = 0.04) and most importantly overall survival (p = 0.0003). Cox regression analysis revealed Cripto to be an independent prognostic variable for survival – HR 2.79 (95% CI 1.20–6.50). Conclusion Overexpression of Cripto is associated with high grade poor prognostic breast cancer and a significantly decreased patient survival. Future research is required to confirm these findings and to develop an anti-Cripto humanised antibody for clinical use. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

49. A Comparative Study on Si Activation in GaAs Between Laser Annealing and Rapid Thermal Annealing

Author

Ong, C. Y., Pey, K. L., Ng, C. M., Ong, B. S., Wong, C. P., Shen, Z. X., Xing, Z. X., Wang, X. C., Zheng, H. Y., and Chan, L.

Abstract

This work studies the use of pulsed laser annealing (LA) to realize high n-type dopant activation in GaAs. The results show that the defects induced by ion implantation can be effectively eliminated by pulsed LA. Besides preserving a good crystalline structure, a much higher dopant activation can be achieved by LA compared to the conventional rapid thermal annealing technique. The high levels of dopant activation obtained in the laser-annealed GaAs samples are attributed to the out-diffusion of the Zn dopant atoms (the p-type dopant of the GaAs substrate) as well as the Ga atoms from the substrate. Diodes activated by an appropriate fluence exhibit excellent rectifying characteristics.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results